Short answer
Benitec Biopharma Inc. (BNTC) filed an 8-K current report with the SEC on September 24, 2026 reporting Item 4.01 (Changes in Registrant's Certifying Accountant). Auditor change: Baker Tilly dismissed September 18, 2026, after serving since 2020.
- This filing includes Item 4.01, an item that often signal trouble.
Benitec Biopharma Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 4.01 · Changes in Registrant's Certifying Accountant
- Auditor change: Baker Tilly dismissed September 18, 2026, after serving since 2020
- Ernst & Young appointed for fiscal 2027, pending completion of client acceptance
- Prior Baker Tilly opinions for fiscal 2026 and 2025 unqualified, with no going-concern modifications
- Previously reported internal-control weakness over share-based compensation, remediated as of June 30, 2026
- No accounting disagreements or reportable events involving either auditor beyond the remediated weakness
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Benitec Biopharma Inc. 8-K filings
Get the next BNTC 8-K as it lands
Follow BNTC for push alerts, or ask the research agent what this filing means.